Preclinical investigations have evaluated and validated the tumor-killing efficacy of a CD16/CD33 BiKE against MDS as well as AFM13, a CD16/CD30 BiKE against CD30+ lymphomas [178,179]. This evidence concerns the gene TNFRSF8 and neoplasm.